Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Foot stimulation reduces bedwetting frequency among children with nocturnal enuresis

10 Nov 2016

Transcutaneous foot stimulation shows utility as a non-invasive, at-home treatment for reducing the number of bedwetting episodes in children with nocturnal enuresis, according to a recent study.

A total of 22 paediatric patients (mean age 11.4 years) with ≥2 bedwetting episodes per week for at least 3 consecutive months were included in the study. All patients received a 60-minute session of stimulation of peripheral tibial nerve branches nightly for 2 weeks.

The patients kept a nighttime voiding diary for 6 weeks: 2 weeks prior to the stimulation, 2 weeks during the intervention, and 2 weeks post-stimulation.

Overall, the intervention produced a significant reduction in mean total wet nights from 9 at baseline to 6.8 during the stimulation period (p<0.01). This reduction was sustained during the post-stimulation period (7.2 wet nights; p=0.02).

A reduction of at least 1 episode of bedwetting occurred in 72.7 percent of the patients during the stimulation period. The mean number of wet nights improved from 7.9 to 4.8 (p<0.01). The improvement was maintained at a mean of 5.1 during the post-stimulation period (p<0.01).

The beneficial effect of electrical stimulation of somatic afferent pathways (in the pudendal nerve, posterior tibial nerve, or sacral spinal roots) on bladder activity is well-established. This method has been shown to be effective in both humans and animals. However, sacral and pudendal neuromodulation involves a stimulator implant, while tibial nerve neuromodulation requires percutaneous insertion of a needle electrode cephalad to the medial malleolus. These treatments are inconvenient and costly. [BJUI 2011;107;303–309]

The current data highlight the potential of noninvasive transcutaneous stimulation of somatic nerves in the foot in the management of nocturnal enuresis in children.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.